ILA — Island Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- AU$6.03m
- AU$5.56m
- AU$0.01m
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0 | 0 | 0 | 0.011 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Total Operating Expenses | 0.001 | 2.14 | 2.81 | 2.91 |
Operating Profit | -0.001 | -2.14 | -2.81 | -2.9 |
Total Net Non Operating Interest Income / Expense | ||||
Net Income Before Taxes | -0.001 | -2.13 | -2.61 | -2.83 |
Provision for Income Taxes | ||||
Net Income After Taxes | -0.001 | -2.13 | -2.61 | -2.83 |
Net Income Before Extraordinary Items | ||||
Net Income | -0.001 | -2.13 | -2.61 | -2.83 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -0.001 | -2.13 | -2.61 | -2.83 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0 | -0.023 | -0.029 | -0.031 |
Dividends per Share |